GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » EV-to-FCF

Dechra Pharmaceuticals (LSE:DPH) EV-to-FCF : 145.09 (As of Apr. 29, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Dechra Pharmaceuticals's Enterprise Value is £4,831.4 Mil. Dechra Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was £33.3 Mil. Therefore, Dechra Pharmaceuticals's EV-to-FCF for today is 145.09.

The historical rank and industry rank for Dechra Pharmaceuticals's EV-to-FCF or its related term are showing as below:

LSE:DPH' s EV-to-FCF Range Over the Past 10 Years
Min: -132.05   Med: 48.39   Max: 227.36
Current: 145.09

During the past 13 years, the highest EV-to-FCF of Dechra Pharmaceuticals was 227.36. The lowest was -132.05. And the median was 48.39.

LSE:DPH's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 22.655 vs LSE:DPH: 145.09

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), Dechra Pharmaceuticals's stock price is £38.66. Dechra Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.247. Therefore, Dechra Pharmaceuticals's PE Ratio for today is At Loss.


Dechra Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Dechra Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals EV-to-FCF Chart

Dechra Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.38 55.97 -107.86 87.34 138.98

Dechra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -107.86 - 87.34 - 138.98

Competitive Comparison of Dechra Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dechra Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Dechra Pharmaceuticals's EV-to-FCF falls into.



Dechra Pharmaceuticals EV-to-FCF Calculation

Dechra Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4831.424/33.3
=145.09

Dechra Pharmaceuticals's current Enterprise Value is £4,831.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Dechra Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was £33.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dechra Pharmaceuticals  (LSE:DPH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Dechra Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=38.66/-0.247
=At Loss

Dechra Pharmaceuticals's share price for today is £38.66.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Dechra Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.247.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Dechra Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Dechra Pharmaceuticals (LSE:DPH) Business Description

Traded in Other Exchanges
Address
24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines